Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

This early-phase study is testing a new type of immune cell therapy — engineered natural killer (NK) cells from donated cord blood, programmed to target a protein called CD70 — in people with advanced kidney cancer (clear cell renal cell carcinoma), mesothelioma (a lung lining cancer), or bone cancer (osteosarcoma) that has not responded to prior treatments. **You may be eligible if...** - You have advanced clear cell renal cell carcinoma, mesothelioma, or osteosarcoma - Your tumor expresses the CD70 protein (confirmed by biopsy) - You are in reasonably good health (ECOG performance score 0 or 1) - It has been at least 2 weeks since your last chemotherapy or targeted therapy - It has been at least 3 months since any previous cell therapy - Your organ function (kidneys, liver, heart, lungs) meets the required levels **You may NOT be eligible if...** - Your tumor does not express CD70 - You have had too recent prior treatments - Your organ function does not meet minimum requirements - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.